BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
Status:
Terminated
Trial end date:
2018-07-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of BeEAM (bendamustine,
etoposide, cytarabine and melphalan) regimen prior to autologous stem cell transplant for
first and second chemosensitive relapses in patients with follicular lymphoma (World Health
Organisation (WHO) grade 1, 2, 3a).